Enveric Biosciences Inc Stock Price, News & Analysis

Enveric Biosciences (NASDAQ: ENVB) announced the publication of two significant peer-reviewed research papers showcasing innovative bioproduction methods for neuropsychiatric drug discovery. The first paper in ACS Chemical Biology details the creation of 279 tryptamine derivatives, including 17 novel compounds showing interaction with melatonin and serotonin receptors. The second paper in BioDesign Research presents the first-ever bioproduction method for MDMA and related compounds using engineered yeast.

The company's lead candidate EB-003, manufactured through traditional synthetic chemistry, represents a novel class of neuroplastogens targeting both 5-HT₂A and 5-HT₁B receptors. Enveric plans to submit an Investigational New Drug (IND) application with first-in-human studies expected in 2026.

Enveric Biosciences (NASDAQ: ENVB) has received FDA response regarding its pre-IND Type B meeting request for EB-003, its lead neuroplastogenic program. The FDA recommended that Enveric proceed directly to submitting its Investigational New Drug (IND) application, suggesting the company's development strategy is sufficiently advanced.

The company plans to file the IND application for EB-003 in early 2026. EB-003 is designed as a dual-acting compound targeting depression and anxiety through durable neuroplastic changes without hallucinogenic effects. Enveric's intellectual property portfolio includes 26 issued U.S. patents and 60 pending national and international applications.

Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic small molecules, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Joseph Tucker, Ph.D., will deliver a virtual presentation on September 8, 2025, at 7:00 AM ET.

The presentation will highlight the company's pipeline of therapeutics for depression, anxiety, and addiction disorders, featuring their lead candidate EB-003. This compound is designed to provide neuroplastogenic benefits while minimizing hallucinatory effects, with a dual-targeting mechanism showing partial agonism at 5-HT₂A receptor and agonism at 5-HT₁B receptor. Dr. Tucker will also conduct one-on-one meetings with investors and potential partners.

Enveric Biosciences (NASDAQ: ENVB) has announced the relocation of its corporate headquarters to Cambridge, Massachusetts, positioning itself within one of the world's premier biotech hubs. The strategic move aims to leverage the Greater Boston area's scientific and financial ecosystem as the company prepares to advance its lead molecule, EB-003, into first-in-human clinical trials in 2026.

EB-003, representing a novel class of neuroplastogens, is designed to treat neuropsychiatric conditions through dual engagement of 5-HT₂A and 5-HT₁B receptors while minimizing hallucinatory effects. The company plans to submit an Investigational New Drug (IND) application, supported by encouraging preclinical data.

Enveric Biosciences (NASDAQ: ENVB) has successfully completed 7-day Dose Range Finding (DRF) toxicology studies for its lead drug candidate EB-003, a first-in-class neuroplastogen targeting depression, PTSD, and other neuropsychiatric disorders. The studies, conducted in two preclinical species, established the Maximum Tolerated Dose (MTD) and confirmed oral bioavailability with dose-dependent plasma concentration increases.

The results demonstrated CNS-related effects and brain penetration, supporting the compound's intended therapeutic use. EB-003 selectively engages serotonin 5-HT2A and 5-HT1B receptors to promote neural circuit remodeling without inducing hallucinations, potentially enabling outpatient administration for chronic conditions.

Enveric Biosciences (NASDAQ:ENVB) reported Q2 2025 financial results and significant progress in its neuroplastogenic drug development programs. The company's lead candidate, EB-003, demonstrated a novel dual mechanism of action targeting both 5-HT₂A and 5-HT₁B receptors, positioning it as a first-in-class therapeutic for mental health conditions.

Key developments include positive preclinical results in PTSD and chronic depression models, with EB-003 showing rapid extinction of fear responses and significant reduction in behavioral despair. The company is advancing toward an IND submission in early 2026. Financial results showed a net loss of $2.5 million for Q2 2025, with cash reserves of $2.8 million and additional fundraising of $4.9 million in H1 2025.

Enveric also strengthened its IP portfolio with new patent grants and allowances across multiple chemical classes, reinforcing its position in non-hallucinogenic neuroplastogenic compounds.

Enveric Biosciences (NASDAQ: ENVB) has secured a second U.S. patent allowance for its EVM401 Series, covering novel methylone-inspired compounds designed for mental health treatment. The patent, titled "Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives," focuses on non-hallucinogenic benzodioxole derivatives engineered to modulate neurotransmitters for neuropsychiatric disorders.

The compounds are structurally similar to methylone, which has shown positive Phase 2 results in PTSD treatment, but feature unique chemical structures enabling patent protection and potential repeat-dose outpatient care. Unlike methylone, which lacks composition patent exclusivity, Enveric's molecules are fully patentable and proprietary. The company will conduct further preclinical testing to evaluate safety, pharmacokinetics, and effectiveness against PTSD.

Enveric Biosciences (NASDAQ: ENVB) announced positive preclinical results for its lead drug candidate EB-003 in a PTSD model. The study demonstrated that EB-003 significantly decreased context-induced freezing behavior (p < 0.05) in fear-conditioned mice one hour after administration, matching the therapeutic effects of MDMA used as control.

The research, conducted by a third-party lab, utilized a well-established translational rodent model. CEO Joseph Tucker highlighted that current FDA-approved PTSD treatments (SSRIs) achieve only 20-30% full remission rates with delayed onset of benefits. EB-003, as a next-generation neuroplastogen, shows potential to enhance hippocampal neuroplasticity without causing hallucinations, potentially offering a breakthrough in PTSD treatment.

Enveric Biosciences (NASDAQ: ENVB) has announced new data revealing that its lead candidate EB-003 acts as an agonist of the serotonin receptor 5-HT1B, expanding its potential therapeutic applications. The compound demonstrated agonism of 5-HT1B with an EC50 of 110 nM, complementing its known partial agonist activity on the 5-HT2A receptor.

This discovery broadens EB-003's potential applications to include major depressive disorder, Parkinson's disease, migraines, and cluster headaches. The drug candidate is currently in preclinical development, with IND-enabling activities planned through 2025. Previous data had shown positive pharmacology, in vitro safety, and oral bioavailability, including therapeutically relevant brain exposure in rodent models.